Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-07-24
2007-07-24
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024330, C536S024500
Reexamination Certificate
active
10094365
ABSTRACT:
Described herein are methods of inhibiting M-CSF activity, and, in particular, M-CSF/c-fms dependent cell signaling. In a first embodiment of the invention, one administers to a mammal viral vectors that deliver genes experessing antisense c-fms RNA; in a second embodiment, one induces in vivo production of a high-affinity soluble c-fms protein that competes for non-bound M-CSF; in a third embodiment, one administers a ribozyme-viral vector against c-fms mRNA; and in a fourth embodiment, one administers oligodeoxynucleotides that inhibit expression of c-fms gene product. The methods may be used to treat any disease in which M-CSF activity plays a role, and are particularly effective in treating and preventing atherosclerosis.Embodiments of the present invention are directed primarily, but not exclusively, to a method for treating and preventing cardiovascular disease by inhibiting receptors to M-CSF. Other embodiments of the present invention include any and all biologic and/or pathobiologic phenomena mediated in whole or in part by M-CSF signaling through its receptor. Pathobiologic phenomena include, but are not limited to, disease entities such as osteoporosis, Alzheimer's disease, diabetes mellitus (Type 1 and/or Type 2), infectious diseases, cancer, and inherited disorders characterized by defects in one or more components in the M-CSF signaling pathway.
REFERENCES:
patent: 5019381 (1991-05-01), Garnick
patent: 5021239 (1991-06-01), Garnick
patent: 5084556 (1992-01-01), Brown
patent: 5087453 (1992-02-01), Strassmann
patent: 5112961 (1992-05-01), Hayashida et al.
patent: 5186931 (1993-02-01), Kishimoto et al.
patent: 5211947 (1993-05-01), Brannan et al.
patent: 5288487 (1994-02-01), Kawashima et al.
patent: 5290549 (1994-03-01), Garnick
patent: 5340573 (1994-08-01), Garnick
patent: 5475087 (1995-12-01), Seelig et al.
patent: 5629283 (1997-05-01), Nicola et al.
patent: 5635388 (1997-06-01), Bennett et al.
patent: 5650299 (1997-07-01), Lawman et al.
patent: 5658756 (1997-08-01), Rodan et al.
patent: 5705611 (1998-01-01), Hayashida et al.
patent: 5714140 (1998-02-01), Strassmann
patent: 5726036 (1998-03-01), Nicola et al.
patent: 5734039 (1998-03-01), Calabretta et al.
patent: 5747032 (1998-05-01), Metcalf et al.
patent: 5811301 (1998-09-01), Cameron
patent: 5814479 (1998-09-01), Zhou et al.
patent: 5830760 (1998-11-01), Tsai et al.
patent: 5849283 (1998-12-01), Ciliberto et al.
patent: 5851829 (1998-12-01), Marasco et al.
patent: 5866114 (1999-02-01), Pandit et al.
patent: 5866397 (1999-02-01), Rodan et al.
patent: 5874546 (1999-02-01), Nagata et al.
patent: 5888495 (1999-03-01), Schrier et al.
patent: 5891432 (1999-04-01), Hoo
patent: 5914106 (1999-06-01), Ciliberto et al.
patent: 5939063 (1999-08-01), Vadas et al.
patent: 5965371 (1999-10-01), Marasco et al.
patent: 5981708 (1999-11-01), Lawman et al.
patent: 5985265 (1999-11-01), Kinstler et al.
patent: 5997865 (1999-12-01), Bennett et al.
patent: 6004940 (1999-12-01), Marasco et al.
patent: 6025146 (2000-02-01), Pandit et al.
patent: 6033856 (2000-03-01), Koerner et al.
patent: 6046047 (2000-04-01), Crabtree et al.
patent: 6072036 (2000-06-01), Marasco et al.
patent: 6080575 (2000-06-01), Heidtmann et al.
patent: 6100070 (2000-08-01), Zurfluh et al.
patent: 6136957 (2000-10-01), Nicola et al.
patent: WO 01/30381 (2001-05-01), None
Glass et al Atherosclerosis: The Road Ahead. Cell, 2001 vol. 104:503-516.
Branch, A. A Good Antisense is Hard to Find. TIBS, Feb. 1998 vol. 23, pp. 45-50.
Jen et al. Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies. Stem Cells, 2000, vol. 18:307-319.
Yokoyama et al. Modulation of c-fms proto-oncogene in an ovarian carcinoma cell line by a hammerhead ribozyme. British Journal of Cancer, 1997 vol. 76:977-982.
Sansilvestri et al. Blood, 1995 vol. 86, No. 5, pp. 1729-1735. Early CD34 high Cells Can Be Separated into KIT high Cells in which Transforming Growth Factor-beta (TGF-beta) Downmodulates c-kit and KIT low Cells in which Anti-TGF-beta Upmodulates c-kit.
P. Smaglik, “Making Sense of Antisense,”The Scientist, vol. 12[17]:1 (Aug. 1998).
A. D. Branch, “Letter: Making Sense of Antisense,”The Scientist, vol. 12[20]: 8 (Oct. 1998).
“Antisense Drug Against Lymphoma,”Academic Press Daily inScight, http://www.apnet.com/inscight/04171997/grapha.htm (Apr. 18, 1997).
Borycki, Anne-Gaelle, “Colony-Stimulating Factor 1 (CSF-1) Is Involved in an Autocrine Growth Control of Rat Myogenic Cells,”Experimental Cell Research, vol. 218, pp. 213-222 (1995).
Himes et al., “A highly conserved c-fmsgene intronic element controls macrophage-specific and regulated expression,”Journal of Leukocyte Biology, vol. 70, pp. 812-820 (Nov. 2001).
Bocycki, Anne-Gaelle et al., “Repression of the CSF-1 receptor (c-fmsproto-oncogene product) by antisense transfection induces G1-growth arrest in L6×1 rat myoblasts,”Oncogene, vol. 10, pp. 1799-1811 (1995).
Y. Yokoyama et al., “Modulation of c-fmsproto-oncogene in an ovarian carcinoma cell line by a hammerhead ribozyme,”British Journal of Cancer, vol. 76(8), pp. 977-982 (1997).
Sansilvestri, Patricia et al., Early CD34highCells Can Be Separated Into KIThighCells in Which Transforming Growth Factor-β (TGF-β) Downmodulates c-kitand KITlowCells in Which Anti-TGF-β Upmodulates c-kit.
Birchenall-Roberts, Maria C. et al., “Inhibition of Murine Monocyte Proliferation by a Colony-Stimulating Factor-1 Antisense Oligodeoxynucleotide,”The Journal of Immunology, vol. 145, pp. 3290-3296 (Nov. 15, 1990).
T. Inaba and N. Yamada, “Involvement of Transcription Factor PU.1 in Phenotypic Transformation of Vascular Smooth Muscle Cells to Macrophage-like Cells,”Third Department of Internal Medicine(University of Tokyo), vol. 24, No. 4-5 (1996).
J. Wu et al., “The role of the c-fmsoncogene in the regulation of HL-60 cell differentiation,”Oncogene, vol. 5, pp. 873-877 (1990).
T. Inaba et al., “Transcription Factor PU.1 Mediates Induction of c-fmsin Vascular Smooth Muscle Cells: a Mechanism for Phenotypic Change to Phagocytic Cells,”Molecular and Cellular Biology, vol. 16, No. 5, pp. 2264-2273 (May 1996).
Herembert, T. et al.,Control of Vascular Smooth-Muscle Cell Growth by Macrophage-Colony-Stimulating Factor, Biochemical Journal, 325(1):123-128 (1997).
Pavlides G. S. et al.,Intramural Drug Delivery by Direct Injection Within the Arterial Wall : First Clinical Experience With a Novel Intracoronary Delivery-Infiltrator System, Catheterization and Cardiovascular Diagnosis, 41(3):287-292 (Jul. 1997).
Rajavashisth, T. et al.,Heterozygous Osteopetrotic(op)Mutation Reduces Atherosclerosis in LDL Receptor-deficient Mice, Journal of Clinical Investigation, 101(12):2702-2710 (Jun. 15, 1998).
Rajavashisth, T. et al.,Local Adenoviral Delivery of Antisense c-fms Gene Inhibits In-Stent Stenosis in Porcine Coronary Arteries, Circulation, 108(17):IV-6 (Oct. 28, 2003) Supplement.
Davis , Wright, Tremaine, LLP
Gibbs Terra C.
Levy Seth D.
McGarry Sean
LandOfFree
Methods for inhibiting macrophage colony stimulating factor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for inhibiting macrophage colony stimulating factor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting macrophage colony stimulating factor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3797089